Prostaglandin E2 Affects the Tumor Immune Response in Prostatic Carcinoma

Abstract

No AccessJournal of Urology1 Jul 1981Prostaglandin E2 Affects the Tumor Immune Response in Prostatic Carcinoma J. Kaneti, D.M.P. Thomson, and Everett C. Reid J. KanetiJ. Kaneti Current address: Urology Department, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel. More articles by this author , D.M.P. ThomsonD.M.P. Thomson More articles by this author , and Everett C. ReidEverett C. Reid More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)54384-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Antitumor immunity to prostatic carcinoma was assayed by the tube leukocyte adherence inhibition assay. Peripheral blood leukocytes from 37 patients with prostatic carcinoma and 128 patients without prostatic carcinoma were incubated separately with extracts from prostatic carcinoma and from an unrelated control cancer, and the non-adherence index was calculated. The number of patients with prostatic carcinoma who had a positive response (non-adherence index greater or equal to 30) was small. Nevertheless, the mean non-adherence index (11) of the patients with prostatic carcinoma was statistically different (p less than 0.02) from the mean non-adherence index (2) of the subjects without prostatic carcinoma. Of patients with prostatic carcinoma 14 per cent (5 of 37) had positive leukocyte adherence inhibition responses, compared to 1.5 per cent of control subjects (2 of 128) (p less than 0.05). Sixty patients diagnosed clinically as having benign prostatic hyperplasia were screened by the leukocyte adherence inhibition test and the non-adherence index results then were evaluated with the histopathological diagnosis of the surgical specimen. Of the patients with benign prostatic hyperplasia 3 (5 per cent) had stage A prostatic carcinoma, and 1 of these 3 patients (33 per cent) had a positive leukocyte adherence inhibition test. After in vitro treatment of the peripheral blood leukocytes with 10–6 M. prostaglandin E2 11 of 18 patients with prostatic carcinoma (61 per cent) and 1 of 35 subjects without prostatic carcinoma (3 per cent) had positive leukocyte adherence inhibition responses. The ability of prostaglandin E2 to heighten the leukocyte adherence inhibition response of the peripheral blood leukocytes from patients with prostatic carcinoma suggests that there is a functional defect in the antitumor response of the peripheral blood leukocytes, possibly caused in part by an excess of circulating tumor antigen. In fact, this is supported by the high mean non-adherence index (19) in patients with prostatic carcinoma who had serum prostatic acid phosphatase within normal limits, while patients with an elevated prostatic acid phosphatase had a low mean non-adherence index (0.2). Therefore, patients with prostatic carcinoma are expressing an antitumor response to prostatic carcinoma but this response is weak even when the clinical stage of the disease seems to be early. © 1981 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byMori K, Neal D and Lamm D (2018) Immunological Assessment of Renal Cancer Patients as Evaluated by the Lymphocyte Adherence Inhibition TestJournal of Urology, VOL. 136, NO. 3, (571-575), Online publication date: 1-Sep-1986.Mori K, Toshiaki S, Yamagiwa K and Ohkawa T (2018) Mechanism of the LAI Test in Bladder Cancer PatientsJournal of Urology, VOL. 135, NO. 4, (856-861), Online publication date: 1-Apr-1986.Lajzerowicz M, Thomson D and Reid E (2018) A Study of the Immune Response to the Organ-Specific Neoantigen of Human Bladder CancerJournal of Urology, VOL. 128, NO. 5, (1122-1129), Online publication date: 1-Nov-1982. Volume 126Issue 1July 1981Page: 65-70 Advertisement Copyright & Permissions© 1981 by The American Urological Association Education and Research, Inc.MetricsAuthor Information J. Kaneti Current address: Urology Department, Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel. More articles by this author D.M.P. Thomson More articles by this author Everett C. Reid More articles by this author Expand All Advertisement PDF downloadLoading ...